Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Am J Obstet Gynecol. 2010 Apr 24;203(2):162.e1–162.e8. doi: 10.1016/j.ajog.2010.02.056

Table 6.

Log10(IC50) values for USPC primary cell lines treated with drug combinations.

A: Decreases in Log10 IC50 for Carboplatin and Docetaxel when used in combination
Carboplatin Docetaxel Combination Difference P† Fold Decrease
in IC50‡
mean±SD* 1.048±0.444 0.923± 0.405 0.125±0.128 0.0934 1.33
0.493±0.263 −0.178±0.359 0.672±0.346 0.0122 4.70
B: Decreases in Log10 IC50 for Carboplatin and Doxorubicin when used in combination
Carboplatin Doxorubicin Combination Difference P† Fold Decrease
in IC50 ‡
mean±SD* 1.048±0.444 0.675± 0.516 0.373±0.371 0.0878 2.36
1.439±0.649 1.055±0.516 0.384±0.138 0.0034 2.42
C: Decreases in Log10 IC50 for Carboplatin and Gemcitabine when used in combination
Carboplatin Gemcitabine Combination Difference P† Fold Decrease
in IC50 ‡
mean±SD* 1.048±0.444 0.842± 0.491 0.206±0.166 0.0505 1.61
0.851±0.480 0.440±0.333 0.411±0.210 0.0119 2.58
D: Decreases in Log10 IC50 for Carboplatin and Paclitaxel when used in combination
Carboplatin Paclitaxel Combination Difference P† Fold Decrease
in IC50 ‡
mean±SD* 1.048±0.444 0.771± 0.201 0.277±0.270 0.0835 1.89
0.688±0.340 0.072±0.201 0.616±0.455 0.0389 4.13
E: Decreases in Log10 IC50 for Carboplatin and Topotecan when used in combination
Carboplatin Topotecan Combination Difference P† Fold Decrease
in IC50‡
mean±SD* 1.048±0.444 0.770± 0.359 0.278±0.179 0.0254 1.90
0.334±0.553 0.372±0.359 0.961±0.251 0.0010 9.15
*

mean±SD of log10(IC50)s of agents used singly or in combination as shown, calculated for five USPC cell lines (ARK1, ARK2, ARK3, ARK4, and ARK6). Cell line ARK5 was excluded because it was not exposed to combinations.

†

P value, paired t-test.

‡

Fold decrease in IC50 of agents in combination compared to when used as single agents. Fold decrease is calculated as 10 to the power of the mean difference in log10(IC50)s.